INS and type 2 diabetes mellitus: The most significant position of these molecules seems to be as they are asubset of commercially employed noninsulin-dependent diabetes mellitus (NIDDM), insulin sensitizing agents (Figure 1) such as epalrestat, ciglitazone, AD-5061, pioglitazone, rosiglitazone, and so forth.